Cargando…
Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy
Background: Patients with systemic lupus erythematosus (SLE) show increased serum levels of tumor necrosis factor (TNF)/TNF receptor (R) superfamily member, e.g. BAFF (B lymphocyte stimulator). Belimumab, a monoclonal antibody against soluble BAFF, is used for treatment of SLE. Although B cells are...
Autores principales: | Piantoni, Silvia, Regola, Francesca, Masneri, Stefania, Merletti, Michele, Lowin, Torsten, Airò, Paolo, Tincani, Angela, Franceschini, Franco, Andreoli, Laura, Pongratz, Georg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176088/ https://www.ncbi.nlm.nih.gov/pubmed/34093196 http://dx.doi.org/10.3389/fphar.2021.666971 |
Ejemplares similares
-
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
por: Regola, Francesca, et al.
Publicado: (2019) -
B cell alterations during BAFF inhibition with belimumab in SLE
por: Ramsköld, Daniel, et al.
Publicado: (2018) -
Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab
por: Kowalczyk-Quintas, Christine, et al.
Publicado: (2018) -
Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system
por: Lazzaroni, Maria Grazia, et al.
Publicado: (2021) -
The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.
por: Piantoni, Silvia, et al.
Publicado: (2020)